Xenon Pharmaceuticals (NASDAQ:XENE) Insider Sells $156,706.77 in Stock

Xenon Pharmaceuticals Inc. (NASDAQ:XENE) insider Andrea Difabio sold 2,607 shares of Xenon Pharmaceuticals stock in a transaction dated Tuesday, March 10th. The stock was sold at an average price of $60.11, for a total value of $156,706.77. Following the completion of the sale, the insider directly owned 4,893 shares in the company, valued at $294,118.23. This trade represents a 34.76% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.

Xenon Pharmaceuticals Trading Down 2.6%

Shares of NASDAQ:XENE traded down $1.57 during mid-day trading on Wednesday, reaching $59.04. The stock had a trading volume of 5,546,191 shares, compared to its average volume of 1,583,794. The business’s 50 day moving average price is $43.23 and its 200 day moving average price is $41.69. Xenon Pharmaceuticals Inc. has a 1 year low of $26.74 and a 1 year high of $63.95. The company has a market cap of $4.91 billion, a P/E ratio of -13.54 and a beta of 0.91.

Xenon Pharmaceuticals (NASDAQ:XENE) last released its quarterly earnings data on Thursday, February 26th. The biopharmaceutical company reported ($1.31) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.20) by ($0.11). During the same period last year, the company earned ($0.84) earnings per share. Analysts predict that Xenon Pharmaceuticals Inc. will post -3.1 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Xenon Pharmaceuticals

A number of hedge funds have recently modified their holdings of the business. Elevation Point Wealth Partners LLC acquired a new stake in shares of Xenon Pharmaceuticals during the 2nd quarter worth about $32,000. Danske Bank A S acquired a new position in Xenon Pharmaceuticals in the third quarter valued at about $32,000. Blue Trust Inc. boosted its stake in Xenon Pharmaceuticals by 2,560.7% during the fourth quarter. Blue Trust Inc. now owns 745 shares of the biopharmaceutical company’s stock worth $33,000 after buying an additional 717 shares during the period. Kestra Advisory Services LLC purchased a new position in Xenon Pharmaceuticals during the fourth quarter worth about $33,000. Finally, Aster Capital Management DIFC Ltd acquired a new stake in shares of Xenon Pharmaceuticals during the third quarter valued at about $39,000. 95.45% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

XENE has been the subject of several research reports. Needham & Company LLC increased their price objective on shares of Xenon Pharmaceuticals from $58.00 to $80.00 and gave the company a “buy” rating in a research report on Monday. JPMorgan Chase & Co. boosted their target price on shares of Xenon Pharmaceuticals from $60.00 to $62.00 and gave the stock an “overweight” rating in a report on Friday, January 9th. Wells Fargo & Company upped their target price on shares of Xenon Pharmaceuticals from $49.00 to $68.00 and gave the company an “overweight” rating in a research report on Tuesday. HC Wainwright lifted their price target on Xenon Pharmaceuticals from $53.00 to $74.00 and gave the stock a “buy” rating in a research report on Tuesday. Finally, Deutsche Bank Aktiengesellschaft boosted their price objective on Xenon Pharmaceuticals from $56.00 to $90.00 and gave the stock a “buy” rating in a research note on Tuesday. Two research analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and an average target price of $71.94.

Trending Headlines about Xenon Pharmaceuticals

Here are the key news stories impacting Xenon Pharmaceuticals this week:

• Positive Sentiment: Phase 3 X‑TOLE2 trial: azetukalner met its goal in focal‑onset seizures and Xenon said it plans an NDA filing in 3Q‑2026 — a clear clinical milestone that supports future revenue potential. XENE Stock Up as Azetukalner Meets Goal in Focal Onset Seizures Study
• Positive Sentiment: Multiple analyst upgrades and higher price targets (Wells Fargo, Wedbush, HC Wainwright, Deutsche Bank and others) increased street conviction and pushed consensus targets materially above prior levels. That analyst momentum typically supports share appreciation. Deutsche Bank Raises XENE Price Target
• Positive Sentiment: Independent analyst commentary (Needham) expects further upside, reinforcing the buy‑side narrative around azetukalner’s market opportunity. Xenon Pharmaceuticals Stock Price Expected to Rise, Needham & Company LLC Analyst Says
• Neutral Sentiment: Earlier reports noted a proposed $500M offering; that story evolved as management and bankers adjusted size and pricing in response to demand and market conditions. The initial notice itself was informational. Xenon Pharmaceuticals announces proposed $500M public share offering
• Negative Sentiment: Upsized public offering priced at $57.00 per share to raise ~ $650M (with a 30‑day option for additional shares). While the cash strengthens the balance sheet and funds registrational/launch activities, the scale of the sale increases near‑term dilution and likely pressured the stock despite positive trial and analyst news. Xenon Pharmaceuticals Announces Pricing of Upsized $650.0 Million Public Offering

Xenon Pharmaceuticals Company Profile

Xenon Pharmaceuticals Inc is a clinical‐stage biopharmaceutical company dedicated to discovering and developing novel, small‐molecule drugs targeting ion channels in the central and peripheral nervous system. The company’s research focus centers on neurological and pain disorders—including epilepsy, migraine, and neuropathic pain—by modulating key ion‐channel proteins to restore normal neuronal function. Xenon’s scientific platform draws upon advances in ion‐channel biology and structure‐based drug design to identify and optimize therapeutic candidates with the potential for improved safety and efficacy profiles compared with existing treatments.

The company’s pipeline comprises multiple preclinical and clinical programs.